Description of characteristics, management of care and healthcare direct costs of patients with HR+/HER2- early breast cancer in Italy: a real-world study involving administrative and pathological anatomy databases

Figures & data

Figure 1. Flowchart of the study population.

Figure 2. The most frequent type of conservative surgery and mastectomy among HR+/HER2- patients and those with LN removal.

Figure 3. Proportion of patients with distant and local relapse.

Figure 4. Treatments after relapse.

Table 1. Demographic and clinical characteristics of the study population.

CHARACTERISTICS	PATIENTS WITH BREAST CANCER	PATIENTS WITH HR+/HER2-	PATIENTS WITH LN REMOVAL
N	38,837	24,137	3,619
Age, mean (SD) at index date	63.8 (14.1)	63.1 (13.2)	62.4 (13.5)
− 18–39 (n, %)	1,274 (3.3)	652 (2.7)	135 (3.7)
− 40–49 (n, %)	5,717 (14.7)	3,663 (15.2)	610 (16.9)
− 50–59 (n, %)	8,611 (22.2)	5,503 (22.8)	819 (22.6)
− 60–69 (n, %)	8,957 (23.1)	5,918 (24.5)	806 (22.3)
− 70–79 (n, %)	8,382 (21.6)	5,590 (23.2)	833 (23.0)
− 80+ (n, %)	5,896 (15.2)	2,811 (11.6)	416 (11.5)
Charlson index (mean, SD)	0.5 (0.7)	0.5 (0.7)	0.5 (0.7)
− 0 (n, %)	23,815 (61.3)	15,128 (62.7)	2182 (60.3)
− 1 (n, %)	11,210 (28.9)	6,907 (28.6)	1068 (29.5)
− 2+ (n, %)	3,812 (9.8)	2,102 (8.7)	369 (10.2)
Pt with previous hospitalizations related to breast cancer*	2,177 (5.6)	1,055 (4.4)	262 (7.2)
Follow-up, months (mean, SD)	32.3 (20.8)	37.0 (18.9)	38.5 (19.2)
Follow-up, months (median, Q1-Q3)	33.2 (17.0–50.6)	36.9 (21.2–52.7)	38.7 (22.4–54.5)

Note. *All data availability periods before index date.

Table 2. Presence of metastasis at distant relapse.

Metastasis	PATIENTS WITH HR+/HER2- (N = 24,137)	PATIENTS WITH LN REMOVAL (N = 3,619)
Brain metastasis (n, %)	97 (0.4)	35 (1.0)
Bone metastasis (n, %)	395 (1.6)	122 (3.4)
Liver metastasis (n, %)	306 (1.3)	107 (3.0)
Respiratory organ metastasis (n, %)	234 (1.0)	67 (1.9)
Adrenal gland metastasis (n, %)	11 (<0.0)	0 (0.0)
Peritoneum metastasis (n, %)	67 (0.3)	14 (0.4)
Other metastasis (n, %)	110 (0.5)	30 (0.8)
Skin metastasis (n, %)	73 (0.3)	25 (0.7)

Note. NR: not reported for data privacy (<4 patients involved).

Figure 5. Mean annual direct costs during the first year of the follow-up period among alive patients with HR+/HER2- status (N = 21,365) and among those with LN removal (N = 3,539).